Laboratoires Servier

From Wikipedia, the free encyclopedia
  (Redirected from Servier Laboratories)
Jump to: navigation, search
Servier
Type Private
Industry Pharmaceuticals
Founder(s) Jacques Servier
Headquarters Neuilly-sur-Seine, France
Products Coversyl
Revenue €3.5 billion
Employees 20,000
Website www.servier.com
This article is about the pharmaceutical company. For other meanings, see Servier (disambiguation).

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression.[1] The consolidated turnover for the 2005/2006 financial year was €3.5 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 140 countries, achieving 82% of its sales outside France.[1] The annual sales of its ACE inhibitor, Coversyl (perindopril), in 2006 and 2007 exceeded 1 billion US dollars, making it Servier's highest-selling product.[citation needed]

The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 20,000 employees worldwide. The company's production sites produced 670 million drug boxes in 2006.[1]

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[2] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[3]

Product portfolio[edit]

Notable products:

Other products:

Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[5][6] Further investigations found that many previous safety alerts on that drug had been either missed or hushed down, possibly through improper influence of the company.[6]

Collaborative research[edit]

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[7][8] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[9]

References[edit]

  1. ^ a b c "SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression". Retrieved 2007-07-08. 
  2. ^ "Servier UK - Key figures". Retrieved 2007-07-08. 
  3. ^ "The Pharmaceutical Industry in Figures - 2008 Edition" (in english). European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Retrieved 2008-08-25. 
  4. ^ "SERVIER - product portfolio". Archived from the original on 2007-07-02. Retrieved 2007-07-08. 
  5. ^ Article of the Figaro about Mediator
  6. ^ a b Un doute sur la «sécurité» du Mediator dès 1998 - Libération
  7. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.  edit
  8. ^ "InnoMed PredTox Member Organizations". Retrieved 2008-08-25. 
  9. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25. [dead link]

External links[edit]